ARTICLE | Finance

Gilead's arithmetic problem

How much revenue Gilead must add to regain growth rate of big biotech peers

August 1, 2016 7:00 AM UTC

Declining HCV sales and lower guidance from Gilead Sciences Inc. (NASDAQ:GILD) shaved about $10 billion off the bellwether's market cap last Tuesday and renewed investor calls for the company to do a splashy deal to vault its growth back in line with peers.

On July 25, Gilead trimmed its 2016 net sales guidance to $29.5-$30.5 billion from $30-$31 billion after reporting 2Q16 sales of $7.7 billion, down from $8.1 billion in 2Q15. HCV drug sales sank to $4 billion from $4.9 billion. ...